Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. - Wikidata - wikimedia - TriplyDB

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

http://www.wikidata.org/entity/Q40818917

about

Zygomycetes in human disease Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid Clinical Translation of Nanomedicine.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Unusual lipid structures selectively reduce the toxicity of amphotericin B.In vivo stability of ester- and ether-linked phospholipid-containing liposomes as measured by perturbed angular correlation spectroscopy.Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.Antifungal pharmacodynamics: review of the literature and clinical applications.It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis.Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity.Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans.Amphotericin B: delivery systems.Carrier effects on biological activity of amphotericin B.Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF Effect of lipid composition on activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.Amphotericin B lipid complex therapy of experimental fungal infections in mice Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Optimizing efficacy of amphotericin B through nanomodification.Systemic Candida infections.Fungal infections in cancer patients.Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Clinical experience of targeted therapy.

P2860

Q24514527-8E1079F9-453F-492A-8AAA-C1C9A2B16EB5 Q26740363-0BA61F99-02F9-4257-853E-D22BB85AADFE Q28318068-4347200A-7FC7-4D53-9878-56BE981B96A1 Q28328605-0E1D9319-CAC9-46FD-96E3-FB2DB5695F18 Q28333669-16BD88D5-4718-437D-8260-3A93B0229FF1 Q28333963-B741E2C4-F85B-46C5-A340-34FD7B546930 Q28343168-CF476833-C607-4482-BA31-46E8B87A09E5 Q28369708-8B145884-7ACF-4051-91F9-DA3F911C3BA7 Q30355939-D0474C80-8151-4513-A2F4-EE5309C5F458 Q32052950-211F4BB2-E4D2-496B-9D21-B44BAA966950 Q33641360-4DDC652B-45F5-4730-B722-D5A1CA767009 Q33688411-0B8D3CA6-ABE3-4645-8669-8C499E449B47 Q33692176-282E77E7-C631-453E-BFA6-7CAE73031D89 Q33749615-5DE00E69-ADBD-47F2-A739-419C03FE6B4D Q34083129-5796941E-3C58-4C57-8D8F-5C2808B76B94 Q34302880-54CB859B-08F0-4E0F-82DD-A050459DC4EA Q35041474-4CA7B281-6D32-49CD-B147-16D3165CA42E Q35088834-8E4309CA-929B-4556-9F75-69C8C2E3C034 Q35118404-738F2C98-BA23-440A-A2E9-15F9A7FA6DD4 Q35126170-93584577-9A8C-4A57-B008-40AF653D43FB Q35130708-010DA9AC-5F62-4298-BAF0-5499687C455B Q35244089-EDE6AC55-7923-43BE-A2FE-6910A2DF16B3 Q35249721-D55E4212-F5D0-4261-AD0B-D9CD3F7D2FC3 Q35372581-A9DE5C3C-6745-4C6A-AA36-B7BC33415D70 Q35537748-9B6D6F2A-30A1-4AFC-A3BF-AA617E8D2752 Q35562602-E710A71D-6B04-483C-AB45-54D9631D0720 Q35563027-3CBE6D56-5028-440A-9FD8-0F998D352FA5 Q35564495-7911D77E-6725-441F-BDC5-0211BCEFADE8 Q35650338-91BB675E-6343-4644-AED5-A894A989486A Q35653579-E63AD4F7-931D-472C-88D9-B92915B8FDA3 Q35825552-38E1D903-26C7-475B-A5F7-043F64D2CE0A Q35885347-C66D5B3D-1E70-4156-BB84-2EA315C82F23 Q36753279-85105CBB-F710-4034-B864-E8307D6E8CB5 Q36753723-B5C16FE5-4766-47E5-A7FC-C531F02AEE46 Q36758184-1B82C973-6648-4D74-AE94-A7F2EF81303F Q36920328-3AB43795-3571-4EC4-A833-A5A795CAF421 Q36987671-DB3D3756-69E6-443B-A661-91A1F1A9EC2B Q37220788-33484D95-C01D-48E1-90B3-95B798C07C4F Q37650345-476027D5-10A1-4046-83A3-B54E79830295 Q37679162-EDBE0A84-89AB-4562-813A-5E9A92FBF973

P2860

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

http://www.wikidata.org/entity/Q40818917

description

1985 nî lūn-bûn

@nan

1985年の論文

@ja

1985年論文

@yue

1985年論文

@zh-hant

1985年論文

@zh-hk

1985年論文

@zh-mo

1985年論文

@zh-tw

1985年论文

@wuu

1985年论文

@zh

1985年论文

@zh-cn

name

Liposomal amphotericin B for t ...... h cancer: a preliminary study.

@en

type

label

Liposomal amphotericin B for t ...... h cancer: a preliminary study.

@en

prefLabel

Liposomal amphotericin B for t ...... h cancer: a preliminary study.

@en

P1433

Q40818917-E66C2A96-0D39-4415-805E-EC80338B678D

P1476

Q40818917-1B22D7C1-55D3-4885-96CB-AF9330BE1F86

P2093

Q40818917-0141F7D2-946A-404F-A26C-3F8C962B0659

Q40818917-3342A8C8-80B2-473A-8917-E208C1CB805A

Q40818917-34863A24-CF06-4B7B-9787-1BAC944D9604

Q40818917-6F494649-E322-486F-A646-9BCF88A85B1E

Q40818917-846229BD-98C1-4F67-9C31-F94932FE8308

Q40818917-96D2543B-9340-4645-BCA7-5E04B251AD88

Q40818917-AED33551-4F5A-4464-8AD5-A04F5CE2CA3D

Q40818917-E548378D-FD2C-4156-BA9C-A9C1398D8477

Q40818917-E96FCC41-DD87-4194-88F9-7021F307B6C0

Q40818917-EE25BE3D-6336-424B-9EA3-58546B635736

P304

Q40818917-53EC671F-5061-494F-BDB3-A67FFC8880E2

P31

Q40818917-0F4F8AE2-8CDB-4254-B3EB-58099B5592BC

P356

Q40818917-647FB5FF-7663-47CA-9D4E-7837A7ED368D

P407

Q40818917-3864A593-D617-4D8E-A25A-A0A46A2AFC0F

P433

Q40818917-8D30B039-05DD-4469-A3B2-EC900E983869

P478

Q40818917-35CC0E89-B1B3-48FD-B998-62478B74324A

P577

Q40818917-79BBFCDF-8D9D-434F-A0CB-4E10E26EFDD6

P698

Q40818917-72F6D97D-B2AD-45A3-8DD8-040DCD8F0101

P921

Q40818917-8262C846-B1D8-4335-BD67-21270971064D

P356

P1433

The Journal of Infectious Diseases

P1476

Liposomal amphotericin B for t ...... h cancer: a preliminary study.

@en

P2093

Fainstein V

http://www.w3.org/2001/XMLSchema#string

Hersh EM

http://www.w3.org/2001/XMLSchema#string

Hopfer R

http://www.w3.org/2001/XMLSchema#string

Keating M

http://www.w3.org/2001/XMLSchema#string

Lopez-Berestein G

http://www.w3.org/2001/XMLSchema#string

Luna M

http://www.w3.org/2001/XMLSchema#string

Mehta K

http://www.w3.org/2001/XMLSchema#string

Mehta R

http://www.w3.org/2001/XMLSchema#string

Rosenblum MG

http://www.w3.org/2001/XMLSchema#string

Sullivan MP

http://www.w3.org/2001/XMLSchema#string

P304

704-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/151.4.704

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

151

http://www.w3.org/2001/XMLSchema#string

P577

1985-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

3973417

http://www.w3.org/2001/XMLSchema#string

P921